Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating

We recently published an article titled 11 High Growth Micro-cap Stocks to Buy.  On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while maintaining a Neutral rating, reflecting a selective stance toward SMID-cap biotech heading into 2026. While Citi sees opportunity in commercial or near-commercial stage companies, its broader outlook favored other names, highlighting the importance of upcoming clinical and regulatory catalysts in determining r ...